Login to Your Account



Gilead Goes Before Panel Today Seeking Approval Of HBV Drug

By Kim Coghill


Tuesday, August 6, 2002
Gilead Sciences Inc., seeking its second significant product approval in a year, is going before an FDA advisory panel today that is expected to issue a recommendation on Gilead's new drug application for adefovir dipivoxil, a once-daily oral treatment for hepatitis B. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription